DJE Kapital AG Purchases New Holdings in Zoetis Inc. (NYSE:ZTS)

DJE Kapital AG purchased a new stake in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 133,423 shares of the company’s stock, valued at approximately $21,670,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Hancock Whitney Corp increased its position in shares of Zoetis by 0.3% during the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock worth $3,628,000 after acquiring an additional 61 shares during the period. Strategy Asset Managers LLC increased its position in shares of Zoetis by 3.5% during the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after acquiring an additional 62 shares during the period. VeraBank N.A. increased its position in shares of Zoetis by 4.1% during the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after acquiring an additional 62 shares during the period. Procyon Advisors LLC increased its position in shares of Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after acquiring an additional 63 shares during the period. Finally, Deseret Mutual Benefit Administrators grew its stake in shares of Zoetis by 6.6% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock worth $170,000 after purchasing an additional 65 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group assumed coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. StockNews.com downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday, February 25th. Leerink Partners assumed coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. Finally, Morgan Stanley lowered their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $215.90.

Zoetis Stock Performance

NYSE ZTS opened at $167.58 on Monday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The company has a market capitalization of $75.04 billion, a PE ratio of 30.64, a P/E/G ratio of 2.78 and a beta of 0.90. The company has a fifty day moving average of $166.30 and a two-hundred day moving average of $177.26.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. As a group, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.19%. Zoetis’s dividend payout ratio (DPR) is 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.